Table 3.
Analysis of survival
| Variable | Vaccine-related time-to-treatment failure | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| Median V-TTF (95% CI), months | P value | HR (95% CI) | P value | Median OS (95% CI), months | P value | HR (95% CI) | P value | |
| Cancer type | 0.006 | 0.005 | 0.005 | 0.019 | ||||
| Others | 9.8 (2.3–17.3) | 1.00 | 38.0 (27.5–48.5) | 1.00 | ||||
| Lung | 2.7 (1.8–3.6) | 2.77 (1.36–5.64) | 14.9 (11.4–18.3) | 2.79 (1.18–6.62) | ||||
| Number of metastatic sites | < 0.001 | 0.026 | < 0.001 | 0.121 | ||||
| − 1 | 19.1 (7.8–30.3) | 1.00 | 26.2 (23.8–NR) | 1.00 | ||||
| ≥ 2 | 2.7 (1.7–3.7) | 2.44 (1.11–5.31) | 14.7 (12.4–17.0) | 2.27 (0.80–6.39) | ||||
| PD-L1 TPS | 0.001 | 0.167 | < 0.001 | 0.04 | ||||
| < 1% or unknown | 9.4 (4.0–14.8) | 1.00 | 12.4 (9.6–15.2) | 1.00 | ||||
| ≥ 1% | 2.5 (1.0–3.9) | 0.62 (0.31–1.22) | 38.0 (26.3–49.8) | 0.46 (0.22–0.96) | ||||
| Antibody responsea | < 0.001 | < 0.001 | < 0.001 | 0.261 | ||||
| Low-R | 2.3 (1.5–3.2) | 1.00 | 12.4 (8.0–16.9) | 1.00 | ||||
| High-R | 12.2 (3.5–20.9) | 0.25 (0.12–0.52) | 35.3 (13.4–57.1) | 0.62 (0.28–1.41) | ||||
HR hazard ratio, CI confidence interval, PD-L1 TPS, programmed cell death-ligand 1 tumor proportion score, NR not reached
aLow-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer < 486 BAU/mL after the third dose of vaccine, High-R indicates the subgroup of patients with an anti-RBD-S1 IgG titer ≥ 486 BAU/mL after the third dose of vaccine